Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 21,803,852
  • Shares Outstanding, K 118,848
  • Annual Sales, $ 492,850 K
  • Annual Income, $ -858,280 K
  • 60-Month Beta 1.22
  • Price/Sales 45.90
  • Price/Cash Flow N/A
  • Price/Book 27.50
Trade ALNY with:

Options Overview

Details
  • Implied Volatility 59.84%
  • Historical Volatility 28.09%
  • IV Percentile 79%
  • IV Rank 52.41%
  • IV High 74.45% on 07/26/21
  • IV Low 43.75% on 04/16/21
  • Put/Call Vol Ratio 0.43
  • Today's Volume 1,740
  • Volume Avg (30-Day) 1,702
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 8,030
  • Open Int (30-Day) 16,732

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -1.50
  • Number of Estimates 9
  • High Estimate -1.21
  • Low Estimate -1.72
  • Prior Year -2.18
  • Growth Rate Est. (year over year) +31.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
181.96 +0.82%
on 09/20/21
208.55 -12.03%
on 08/27/21
-14.32 (-7.24%)
since 08/20/21
3-Month
154.02 +19.12%
on 06/28/21
209.73 -12.52%
on 08/11/21
+6.57 (+3.71%)
since 06/18/21
52-Week
119.29 +53.79%
on 10/30/20
209.73 -12.52%
on 08/11/21
+51.20 (+38.71%)
since 09/18/20

Most Recent Stories

More News
Alnylam (ALNY) Files MAA to EMA for Rare Disease Drug Vutrisiran

Alnylam (ALNY) submits a marketing authorization application to the EMA for vutrisiran to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.

ALNY : 183.46 (-3.61%)
VRTX : 185.67 (-1.40%)
CRVS : 6.17 (+15.98%)
SPRO : 19.00 (-0.78%)
Alnylam Submits Marketing Authorization Application to the European Medicines Agency for Investigational Vutrisiran for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA)...

ALNY : 183.46 (-3.61%)
RNAi Technology Market Size, Share, Value, Competitive landscape, Industry outlook and Future Forecast till 2027

Research Nester released a report titled ": Global Demand Analysis & Opportunity Outlook 2027" which delivers detailed overview of the global RNAi technology market in terms of market segmentation by therapy...

ALNY : 183.46 (-3.61%)
DRNA : 20.82 (-3.66%)
ARWR : 62.40 (-3.90%)
IONS : 36.19 (-2.74%)
ABUS : 4.29 (-1.38%)
BLT : 10.00 (+0.20%)
SLN.LN : 545.000 (-1.27%)
Alnylam Presents Additional 9-Month Data from HELIOS-A Phase 3 Study of Vutrisiran at the European ATTR (EU-ATTR) Amyloidosis Meeting

--- Additional Analyses Showed Similar Improvements in Progression of Neuropathy and Quality of Life Measures with Vutrisiran Treatment Compared with Placebo, Regardless of Prior TTR Stabilizer Use -

ALNY : 183.46 (-3.61%)
Alnylam Completes Enrollment in HELIOS-B Phase 3 Study of Investigational Vutrisiran in Patients with Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has achieved full patient enrollment in its HELIOS-B Phase 3 study of vutrisiran, an investigational...

ALNY : 183.46 (-3.61%)
Alnylam's (ALNY) Q2 Earnings Miss Estimates, 2021 Guidance Up

Alnylam (ALNY) misses Q2 estimates for earnings but beats the same for sales. The company raises revenue guidance for 2021.

REGN : 640.89 (-1.69%)
SNY : 47.89 (-1.01%)
ALNY : 183.46 (-3.61%)
NVS : 82.80 (-0.81%)
Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Tops Revenue Estimates

Alnylam (ALNY) delivered earnings and revenue surprises of -2.55% and 10.40%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

ALNY : 183.46 (-3.61%)
Alnylam: Q2 Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Alnylam Pharmaceuticals Inc. (ALNY) on Tuesday reported a loss of $189.6 million in its second quarter.

ALNY : 183.46 (-3.61%)
Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity

--a^' Advanced Vutrisiran with New Drug Application (NDA) Submission to the U.S. Food and Drug Administration (FDA) for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis (hATTR-PN); Received...

ALNY : 183.46 (-3.61%)
Drug/Biotech Stock Q2 Earnings on Aug 3: LLY, AMGN & More

Let us take a look at four drug/biotech companies, LLY, AMGN, INCY and ALNY, which are gearing up for their earnings release.

ALNY : 183.46 (-3.61%)
LLY : 231.64 (+0.67%)
AMGN : 215.11 (-1.95%)
INCY : 75.91 (-0.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies,...

See More

Key Turning Points

3rd Resistance Point 193.29
2nd Resistance Point 190.73
1st Resistance Point 187.09
Last Price 183.46
1st Support Level 180.89
2nd Support Level 178.33
3rd Support Level 174.69

See More

52-Week High 209.73
Last Price 183.46
Fibonacci 61.8% 175.18
Fibonacci 50% 164.51
Fibonacci 38.2% 153.84
52-Week Low 119.29

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar